| AASLD | American Association for the Study of Liver Diseases |
| AE | adverse event |
| ALT | alanine aminotransferase |
| AST | aspartate aminotransferase |
| BMI | body mass index |
| CI | confidence interval |
| CRP | C-reactive protein |
| DLD | diabetic liver disease |
| DPP-4 | dipeptidyl peptidase-4 |
| ELF | enhanced liver fibrosis |
| FIB-4 | fibrosis-4 |
| HCC | hepatocellular carcinoma |
| HR | hazard ratio |
| JAZF1 | juxtaposed with another zinc finger gene 1 |
| MRE | magnetic resonance elastography |
| MRI-PDFF | magnetic resonance imaging-proton density fat fraction |
| NAFLD | nonalcoholic fatty liver disease |
| NASH | nonalcoholic steatohepatitis |
| NAS | NAFLD activity score |
| NFS | NAFLD fibrosis score |
| NIT | non-invasive test |
| OGTT | oral glucose tolerance test |
| OR | odds ratio |
| PNPLA3 | patatin-like phospholipase-3 |
| RR | risk ratio |
| SMR | standardized mortality rate |
| T2D | type 2 diabetes |
| TRX | thioredoxin |